Maintenance therapy for multiple myeloma
A next step after your autologous hematopoietic stem cell transplant

REVLIMID® (lenalidomide) is a prescription medicine, used to treat people with multiple myeloma (MM) as maintenance treatment after autologous hematopoietic stem cell transplantation (a type of stem cell transplant that uses your own stem cells).

REVLIMID should not be used to treat people who have chronic lymphocytic leukemia (CLL) unless they are participants in a controlled clinical trial.

It is not known if REVLIMID is safe and effective in children.

REVLIMID is only available through a restricted distribution program, REVLIMID REMS®.

Please see full Prescribing Information, including Boxed WARNINGS and Medication Guide, in pocket and Important Safety Information on pages 2-10.
Important Safety Information

What is the most important information I should know about REVLIMID?

Before you begin taking REVLIMID, you must read and agree to all of the instructions in the REVLIMID REMS® program. Before prescribing REVLIMID, your healthcare provider will explain the REVLIMID REMS program to you and have you sign the Patient-Physician Agreement Form.

REVLIMID may cause serious side effects; including:

- **Possible birth defects (deformed babies) or death of an unborn baby.** Females who are pregnant or who plan to become pregnant must not take REVLIMID
  
  REVLIMID is similar to the medicine thalidomide (THALOMID®), which is known to cause severe life-threatening birth defects. REVLIMID has not been tested in pregnant females. REVLIMID has harmed unborn animals in animal testing

- **Females must not get pregnant:**
  - For at least 4 weeks before starting REVLIMID
  - While taking REVLIMID
  - During any breaks (interruptions) in your treatment with REVLIMID
  - For at least 4 weeks after stopping REVLIMID

- **Females who can become pregnant:**
  Must have pregnancy tests weekly for 4 weeks, then every 4 weeks if your menstrual cycle is regular, or every 2 weeks if your menstrual cycle is irregular. If you miss your period or have unusual bleeding, you will need to have a pregnancy test and receive counseling

Please see additional Important Safety Information continued on page 4.

Extending your response from a stem cell transplant

Your autologous hematopoietic stem cell transplant (auto-HSCT) is an important step against multiple myeloma. An auto-HSCT can be very effective, and there’s a way you may extend your response: post-transplant maintenance therapy. REVLIMID is the only myeloma treatment that is FDA-approved for maintenance therapy after an auto-HSCT.

Table of Contents

- Important Safety Information .......................................................... 2
- Benefits of Maintenance Therapy .................................................... 12
- REVLIMID Maintenance Therapy .................................................... 13
- Clinical Study Results ........................................................................ 14
- How REVLIMID Works ..................................................................... 16
- How to Take REVLIMID Maintenance Therapy ............................... 17
- Side Effects ....................................................................................... 19
- The REVLIMID REMS® Program ....................................................... 20
- The Importance of Monitoring During Treatment ............................ 22
- Celgene Patient Support® ................................................................. 23
- Frequently Asked Questions (FAQs) ............................................... 25
Important Safety Information (continued)

- Must agree to use 2 different forms of effective birth control at the same time, for at least 4 weeks before, while taking, during any breaks (interruptions) in your treatment, and for at least 4 weeks after stopping REVLIMID. Talk with your healthcare provider to find out about options for effective forms of birth control that you may use to prevent pregnancy
- If you had unprotected sex or if you think your birth control has failed, stop taking REVLIMID immediately and call your healthcare provider right away

- If you become pregnant while taking REVLIMID, stop taking it right away and call your healthcare provider. If your healthcare provider is not available, you can call Celgene Customer Care Center at 1-888-423-5436. Healthcare providers and patients should report all cases of pregnancy to FDA MedWatch at 1-800-FDA-1088, and Celgene Corporation at 1-888-423-5436. There is a pregnancy exposure registry that monitors the outcomes of females who take REVLIMID during pregnancy, or if their male partner takes REVLIMID and they are exposed during pregnancy. You can enroll in this registry by calling Celgene Corporation at the phone number listed above

- REVLIMID can pass into human semen. Males, including those who have had a vasectomy, must always use a latex or synthetic condom during any sexual contact with a pregnant female or a female that can become pregnant while taking REVLIMID, during any breaks (interruptions) in your treatment with REVLIMID, and for up to 4 weeks after stopping REVLIMID
- If a female becomes pregnant with your sperm, you should call your HCP right away. The baby may be exposed to REVLIMID and may be born with birth defects

- Do not have unprotected sexual contact with a female who is or could become pregnant. Tell your healthcare provider if you do have unprotected sexual contact with a female who is or could become pregnant
- Do not donate sperm while taking REVLIMID, during any breaks (interruptions) in your treatment, and for 4 weeks after stopping REVLIMID
- Low white blood cells (neutropenia) and low platelets (thrombocytopenia). REVLIMID causes low white blood cells and low platelets in most people. You may need a blood transfusion or certain medicines if your blood counts drop too low. Your healthcare provider should check your blood counts often especially during the first several months of treatment with REVLIMID, and then at least monthly. Tell your healthcare provider if you develop any bleeding or bruising, during treatment with REVLIMID
- Blood clots. Blood clots in the arteries, veins, and lungs happen more often in people who take REVLIMID. This risk is even higher for people with multiple myeloma who take the medicine dexamethasone with REVLIMID. Heart attacks and strokes also happen more often in people who take REVLIMID with dexamethasone. To reduce this increased risk, most people who take REVLIMID will also take a blood thinner medicine

Before taking REVLIMID, tell your healthcare provider:
- If you have had a blood clot in the past
- If you have high blood pressure, smoke, or if you have been told you have a high level of fat in your blood (hyperlipidemia)
- About all the medicines you take. Certain other medicines can also increase your risk for blood clots
Important Safety Information (continued)

Call your healthcare provider or get medical help right away if you get any of the following during treatment with REVLIMID:

- **Signs or symptoms of a blood clot in the lung, arm, or leg may include:** shortness of breath, chest pain, or arm or leg swelling
- **Signs or symptoms of a heart attack may include:** chest pain that may spread to the arms, neck, jaw, back, or stomach area (abdomen), feeling sweaty, shortness of breath, feeling sick or vomiting
- **Signs or symptoms of stroke may include:** sudden numbness or weakness, especially on one side of the body, severe headache or confusion, or problems with vision, speech, or balance

Who should not take REVLIMID?

- Do not take REVLIMID if you are pregnant, plan to become pregnant, or become pregnant during treatment with REVLIMID. See “What is the most important information I should know about REVLIMID?”
- Do not take REVLIMID if you are allergic to lenalidomide or any of the ingredients in REVLIMID. See the Medication Guide for a complete list of ingredients in REVLIMID

What should I tell my healthcare provider before taking REVLIMID?

Before you take REVLIMID, tell your healthcare provider about all of your medical conditions, including if you:

- have liver problems
- have kidney problems or receive kidney dialysis treatment
- have thyroid problems
- are lactose intolerant. REVLIMID contains lactose
- are breastfeeding. REVLIMID must not be used by females who are breastfeeding. It is not known if REVLIMID passes into your breast milk and can harm your baby

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. REVLIMID and other medicines may affect each other, causing serious side effects. Talk with your healthcare provider before taking any new medicines.

Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist.

How should I take REVLIMID?

Take REVLIMID exactly as prescribed and follow all the instructions of the REVLIMID REMS program

- Swallow REVLIMID capsules whole with water 1 time a day. Do not open, break, or chew your capsules
- **REVLIMID may be taken with or without food**
- Take REVLIMID at about the same time each day
- Do not open the REVLIMID capsules or handle them any more than needed. If you touch a broken REVLIMID capsule or the medicine in the capsule, wash the area of your body right away with soap and water
- If you miss a dose of REVLIMID and it has been less than 12 hours since your regular time, take it as soon as you remember. If it has been more than 12 hours, just skip your missed dose. Do not take 2 doses at the same time
- If you take too much REVLIMID, call your healthcare provider right away
- Do not share REVLIMID with other people. It may cause birth defects and other serious problems

REVLIMID is only available through a restricted distribution program, REVLIMID REMS®.
Important Safety Information (continued)

What should I avoid while taking REVLIMID?

- See “What is the most important information I should know about REVLIMID?”
- **Females:** Do not get pregnant and do not breastfeed while taking REVLIMID
- **Males:** Do not donate sperm
- **Do not donate blood** while you take REVLIMID, during any breaks (interruptions) in your treatment, and for 4 weeks after stopping REVLIMID. If someone who is pregnant gets your donated blood, her baby may be exposed to REVLIMID and may be born with birth defects

What are the possible side effects of REVLIMID?

REVLIMID can cause serious side effects, including:

- See “What is the most important information I should know about REVLIMID?”
- **Increased risk of death in people who have chronic lymphocytic leukemia (CLL).** People with CLL who take REVLIMID have an increased risk of death compared with people who take the medicine chlorambucil. REVLIMID may cause you to have serious heart problems that can lead to death, including atrial fibrillation, heart attack, or heart failure. You should not take REVLIMID if you have CLL unless you are participating in a controlled clinical trial
- **Risk of new cancers (malignancies).** An increase in new (second) cancers has happened in patients who received REVLIMID and melphalan, or a blood stem cell transplant, including certain blood cancers, such as acute myelogenous leukemia (AML), and myelodysplastic syndrome (MDS) and certain other types of cancers of the skin and other organs. Talk with your healthcare provider about your risk of developing new cancers if you take REVLIMID

Your healthcare provider will check you for new cancers during your treatment with REVLIMID

- **Severe liver problems, including liver failure and death.** Your healthcare provider should do blood tests to check your liver function during your treatment with REVLIMID. Tell your healthcare provider right away if you develop any of the following symptoms of liver problems:
  - yellowing of your skin or the white part of your eyes (jaundice)
  - dark or brown (tea-colored) urine
  - pain on the upper right side of your stomach area (abdomen)
  - bleeding or bruising more easily than normal
  - feeling very tired

- **Serious allergic reactions and serious skin reactions** can happen with REVLIMID and may cause death. Call your healthcare provider right away if you develop any of these signs or symptoms of a serious allergic reaction or serious skin reaction during treatment with REVLIMID:
  - swelling of your face, eyes, lips, tongue, throat
  - trouble swallowing
  - trouble breathing
  - skin rash, hives, or peeling of your skin
  - blisters

- **Tumor lysis syndrome (TLS).** TLS is caused by the fast breakdown of cancer cells. TLS can cause kidney failure and the need for dialysis treatment, abnormal heart rhythm, seizure and sometimes death. Your healthcare provider may do blood tests to check you for TLS
Important Safety Information (continued)

• Worsening of your tumor (tumor flare reaction). Tell your healthcare provider if you get any of these symptoms of tumor flare reaction while taking REVLIMID: tender swollen lymph nodes, low grade fever, pain, or rash

• Thyroid problems. Your healthcare provider may check your thyroid function before you start taking REVLIMID and during treatment with REVLIMID.

The most common side effects of REVLIMID include:
- diarrhea
- constipation
- itching
- rash
- tiredness
- swelling of the limbs and skin
- nausea
- fever
- cough

These are not all the possible side effects of REVLIMID. Your healthcare provider may tell you to decrease your dose, temporarily stop or permanently stop taking REVLIMID if you develop certain serious side effects during treatment with REVLIMID. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

Please see full Prescribing Information, including Boxed WARNINGS and Medication Guide, in pocket.
Benefits of maintenance therapy

Maintenance therapy is a proven strategy to extend the response from a stem cell transplant (SCT). Maintenance therapy may control the growth of residual myeloma cells.

An SCT is effective in helping multiple myeloma patients significantly reduce myeloma cells and restore the bone marrow’s ability to produce healthy blood cells. Many doctors recommend maintenance therapy following an SCT because it plays an important part in extending the response from a transplant as long as possible.

Why maintenance therapy helps:

- Over 100 million myeloma cells can remain in your body after an SCT—even with a complete response
- Over time, these cells evolve and multiply, and the immune system may not see them or be able to control them
- Without maintenance therapy, your immune system can weaken sooner, and multiple myeloma may return earlier

REVLIMID maintenance therapy

Studies showed that REVLIMID maintenance therapy significantly extended the response from an autologous hematopoietic stem cell transplant (auto-HSCT).

REVLIMID is not a traditional chemotherapy, injection, or infusion

REVLIMID is a once-daily pill, taken at home or wherever is convenient for you. Dosing for REVLIMID maintenance therapy can be adjusted to help reduce side effects, and help people stay on—and receive the benefits of—maintenance therapy longer

REVLIMID is the only multiple myeloma treatment FDA-approved for maintenance therapy after an auto-HSCT.
REVLIMID maintenance therapy delayed disease progression

Two studies (Study 1: 460 patients, Study 2: 614 patients), looked at the efficacy and safety of REVLIMID as a maintenance therapy after an autologous hematopoietic stem cell transplant (auto-HSCT). Half of the patients were treated with REVLIMID every day until the disease progressed, side effects became intolerable or patient withdrawal for another reason, while the other half received no maintenance treatment.

Progression-Free Survival (PFS)

Studies 1 and 2 evaluated Progression-Free Survival (PFS)—how long a patient lives without their disease getting worse.

Initial analyses were conducted in 2009 and 2010 for Study 1 and Study 2, respectively.

• Patients who took REVLIMID maintenance therapy experienced a median* PFS of 2.8 years in Study 1, and 3.4 years in Study 2
• Patients who took no maintenance therapy experienced a median* PFS of 1.6 years (Study 1) and 1.9 years (Study 2)

These studies were updated again for PFS in March 2015 as shown below.

Study 1 showed that the median* PFS for patients on REVLIMID maintenance therapy was 3.8 years longer than patients who received no maintenance therapy.

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Median PFS (Years)</th>
</tr>
</thead>
<tbody>
<tr>
<td>REVLIMID</td>
<td>5.7</td>
</tr>
<tr>
<td>No Maintenance</td>
<td>1.9</td>
</tr>
</tbody>
</table>

Study 2 showed that the median* PFS for patients on REVLIMID maintenance therapy was 1.9 years longer than patients who received no maintenance therapy.

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Median PFS (Years)</th>
</tr>
</thead>
<tbody>
<tr>
<td>REVLIMID</td>
<td>3.9</td>
</tr>
<tr>
<td>No Maintenance</td>
<td>2.0</td>
</tr>
</tbody>
</table>

Additional REVLIMID maintenance therapy clinical data

These studies were not designed to evaluate Overall Survival (OS)—the length of time patients were alive following the start of treatment. Therefore, it cannot be concluded that REVLIMID caused the differences observed between the 2 groups. Below is the Overall Survival data from the studies:

Overall Survival (OS)

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Median OS (Years)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients who took REVLIMID maintenance therapy</td>
<td>9.3</td>
</tr>
<tr>
<td>Patients who took no maintenance therapy</td>
<td>7.0</td>
</tr>
</tbody>
</table>

In Study 1

Patients who took REVLIMID maintenance therapy lived a median* of 9.3 years

Patients who took no maintenance therapy lived a median* of 7.0 years

In Study 2

Patients who took REVLIMID maintenance therapy lived a median* of 8.8 years

 Patients who took no maintenance therapy lived a median* of 7.3 years

* “Median” means half of the patients had a larger result while half of the patients had a smaller result. Study 1 was conducted in the US. Study 2 was conducted in the EU. Talk to your doctor about what this may mean to you.

Important Safety Information

The most common side effects of REVLIMID include: diarrhea, rash, nausea, constipation, tiredness, fever, itching, swelling of the limbs and skin, and cough.

Please see full Prescribing Information, including Boxed WARNINGS and Medication Guide, in pocket and Important Safety Information on pages 2-10.
How REVLIMID works

REVLIMID is an immune-modulating therapy, known as an IMiD® agent, with proven anti-myeloma effects. REVLIMID is an oral therapy that was shown to work in 3 ways in animal models and in vitro*:

*In vitro: in a test tube or glass; outside of a living organism.

STRIKE
Targets and kills myeloma cells

STIMULATE
Helps your immune system recognize and destroy myeloma cells

STARVE
Prevents new myeloma cell growth by starving them of blood

How REVLIMID works

Lenalidomide (REVLIMID) is the only FDA-approved maintenance therapy recommended by the National Comprehensive Cancer Network® (NCCN®) for multiple myeloma.

How to take REVLIMID maintenance therapy

REVLIMID maintenance therapy is taken by itself, without dexamethasone, as maintenance therapy for patients who have had an autologous hematopoietic stem cell transplant (auto-HSCT). It’s a pill you take once a day, at home or wherever is convenient for you.

The standard starting dose for most patients is:

- One 10-mg pill, once daily
- Your doctor may adjust your starting dose based on your specific needs
- After three 28-day cycles of maintenance treatment, the dose of REVLIMID can be increased by your doctor to 15 mg once daily, if tolerated
- This maintenance dosing should continue unless your myeloma gets worse, or if you have side effects that you are unable to tolerate

Be sure to tell your doctor about any unexpected side effects that you experience while taking REVLIMID.

How long do I need to be on REVLIMID maintenance therapy?

REVLIMID maintenance therapy is taken continuously, without a break, as a once-daily pill, unless otherwise directed by your doctor. In clinical trials, patients took REVLIMID maintenance therapy every day, until their disease progressed, they experienced intolerable side effects or patient withdrawal for another reason.
Important things to remember when taking REVLIMID

Swallow REVLIMID capsules whole with water once a day. Do not open, break, or chew your capsules.

Do not open the REVLIMID capsules or handle them any more than needed. If you touch a broken REVLIMID capsule or the medicine in the capsule, wash the area of your body with soap and water.

If you miss a dose of REVLIMID and it has been less than 12 hours since your regular time, take it as soon as you remember. If it has been more than 12 hours, skip your missed dose. Do not take 2 doses at the same time.

If you have kidney problems or are on dialysis, be sure to talk with your doctor. He or she may need to adjust your dose of REVLIMID.

REVLIMID comes in 6 capsule strengths: 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 25 mg. Your doctor will tell you the dose that is right for you.

Your doctor may change your dose. REVLIMID causes low white blood cells (neutropenia) in most patients. You may need a blood transfusion or certain medicines if your blood counts drop too low.

Your healthcare provider should check your blood counts often especially during the first several months of treatment with REVLIMID, and then at least monthly. Tell your healthcare provider if you develop any bleeding or bruising during treatment with REVLIMID.

Side effects

REVLIMID can cause some side effects. Your doctor can adjust your dosage of REVLIMID to help reduce them so you can stay on treatment and receive its benefits longer.

### Serious side effects of REVLIMID:
- Birth defects
- Increased risk of death in people who have chronic lymphocytic leukemia (CLL)
- Risk of new cancers (malignancies)
- Severe liver problems, including liver failure and death
- Serious allergic reactions and serious skin reactions
- Tumor lysis syndrome (TLS)
- Worsening of your tumor (tumor flare reaction)
- Thyroid problems

### Common side effects of REVLIMID include:
- Diarrhea
- Rash
- Nausea
- Constipation
- Tiredness
- Fever
- Itching
- Swelling of the limbs and skin
- Cough

These are not all the possible side effects of REVLIMID. Tell your healthcare team about any side effect that bothers you or does not go away.
REVLIMID REMS® Program

How to receive your first prescription for REVLIMID® (lenalidomide)

MALES

Counseling
Your healthcare provider will counsel you on why and how you and your partner should prevent pregnancy. Your healthcare provider will also inform you not to share the drug, not to donate blood or sperm, and about appropriate contraceptive use. You should be instructed not to extensively handle or open REVLIMID® (lenalidomide) capsules.

Enrollment
You and your healthcare provider will then complete and submit the REVLIMID® (lenalidomide) Patient-Physician Agreement Form.

Complete Mandatory Confidential Survey
You will not have to take a survey for your first prescription, but will have to for the following ones. Visit www.CelgeneRiskManagement.com or call 1-888-423-5436 and press 1 to take your survey.

Prescription
Your healthcare provider will send your prescription to a certified pharmacy.

Pharmacy Call
The certified pharmacy will contact you to provide counseling on the serious risks and safe-use conditions of REVLIMID before you receive your prescription. They will also coordinate delivery of REVLIMID to you.

Receive REVLIMID
REVLIMID will be shipped with a Medication Guide to the address you provide. A signature will be required to receive this shipment.

For each of your following prescriptions, you will need to follow a similar process. For full detailed information about the REVLIMID REMS® program requirements, please visit www.CelgeneRiskManagement.com or review the Patient Guide to REVLIMID REMS® program.

FEMALES

Counseling
Your healthcare provider will counsel you on why and how you and your partner should prevent pregnancy. Your healthcare provider will also inform you not to share the drug, not to donate blood, and about appropriate contraceptive use. You should be instructed not to extensively handle or open REVLIMID® (lenalidomide) capsules.

Pregnancy Test #1
If you can get pregnant, you must take an initial pregnancy test within 10-14 days before getting a REVLIMID prescription.

Pregnancy Test #2
If you can get pregnant, you must take a second pregnancy test within 24 hours before getting a REVLIMID prescription.

Enrollment
You and your healthcare provider will then complete and submit the REVLIMID® (lenalidomide) Patient-Physician Agreement Form.

Complete Mandatory Confidential Survey
You and your healthcare provider will each complete a survey. Visit www.CelgeneRiskManagement.com or call 1-888-423-5436 and press 1 to take your survey.

Prescription
Your healthcare provider will send your prescription to a certified pharmacy.

Pharmacy Call
The certified pharmacy will contact you to provide counseling on the serious risks and safe-use conditions of REVLIMID before you receive your prescription. They will also coordinate delivery of REVLIMID to you.

Receive REVLIMID
REVLIMID will be shipped with a Medication Guide to the address you provide. A signature will be required to receive this shipment.

For each of your following prescriptions, pregnancy tests will be required depending on your ability to get pregnant. For full detailed information about the REVLIMID REMS® program requirements, please visit www.CelgeneRiskManagement.com or review the Patient Guide to REVLIMID REMS® program.
The importance of monitoring during your treatment

When you take REVLIMID maintenance therapy, you’ll need to continue regular monitoring and take certain tests. Your doctor looks for changes from 1 month to the next.

Common tests include:
- Urine
- Blood
- Bone marrow biopsy
- X-rays or other radiology tests

Women taking REVLIMID will also need to take regular pregnancy tests. Please see the REVLIMID REMS® program details on page 20.

Celgene Patient Support®
A single source for access support

At Celgene Patient Support®, we care about making sure you get the answers you need. That’s why our Specialists are ready to help answer questions about the insurance approval process. And you may need help paying for REVLIMID. Celgene Patient Support® can help you and your loved ones understand the programs and services available to you.

Depending on your situation, there are programs and organizations that may help you pay for REVLIMID.

- **Celgene Commercial Co-pay Program**
  for eligible patients with commercial or private insurance (including healthcare exchanges)*

- **Independent third-party organizations**
  for patients who are unable to afford their medication (including patients with Medicare, Medicaid, or other government-sponsored insurance)†

- **Celgene Patient Assistance Program (PAP)**
  for qualified patients who are uninsured or underinsured‡

*Other eligibility requirements and restrictions apply. Please see full Terms and Conditions on the Celgene Patient Support® website.

† Financial and medical eligibility requirements vary by organization.

‡ Patients must meet specified financial and eligibility requirements to qualify for assistance.
Enrollment in Celgene Patient Support® is simple—choose the option that is best for you.

Enroll online at www.celgenepatientsupport.com

Call us at 1-800-931-8691, Monday—Thursday 8 AM—7 PM ET, Friday 8 AM—6 PM ET (translation services available)

Email us at patientsupport@celgene.com

Fax a completed application to 1-800-822-2496

Frequently Asked Questions (FAQs)

Please see full Prescribing Information, including Boxed WARNINGS and Medication Guide, in pocket and Important Safety Information on pages 2-10.
Frequently Asked Questions (FAQs)

Q: I've just had a transplant. Why would I need more treatment?
A: A stem cell transplant (SCT) is effective in helping multiple myeloma patients significantly reduce myeloma cells and restore the bone marrow’s ability to produce healthy blood cells. But after an SCT, 100 million myeloma cells can remain in your body, even with a complete response. Many doctors recommend maintenance therapy following an SCT because it plays an important part in extending the response from a transplant as long as possible.

Q: How long will I need to take treatment?
A: In clinical trials, patients took REVLIMID maintenance therapy every day, until their disease progressed or they experienced intolerable side effects. In studies, low white blood cells (neutropenia) and low platelets (thrombocytopenia) were the most common adverse events that led to discontinuation of REVLIMID maintenance therapy in a small percentage (<3%) of patients. Most patients continued treatment without interruption.

Q: What is the right dose for REVLIMID maintenance therapy?
A: The standard dosing for maintenance therapy with REVLIMID is one 10-mg pill, taken once every day by itself (without dexamethasone). If tolerated, your doctor may increase your dose to 15 mg of REVLIMID once daily.

Q: What can I do to manage side effects?
A: Tell your healthcare team immediately about any side effects you are experiencing, and do not stop taking REVLIMID unless directed. Your doctor can adjust your dose to help reduce side effects. In the case of a severe side effect, your doctor may tell you to discontinue treatment.

Q: What should I do if I miss a dose?
A: If you miss a dose of REVLIMID, and it has been less than 12 hours since your regular time, take it as soon as you remember. If it has been more than 12 hours, skip your missed dose. Do not take 2 doses at the same time.

Q: How should I store REVLIMID?
A: Store REVLIMID at room temperature between 68°F to 77°F (20°C to 25°C). Return any unused REVLIMID to Celgene or your healthcare provider.

Q: Will taking REVLIMID maintenance therapy limit my future treatment options?
A: In REVLIMID maintenance therapy clinical trials, patients went on to receive a variety of other treatment options, including REVLIMID-based regimens.

Q: Why are results from the two clinical trials different?
A: Study 1 and Study 2 were both designed to evaluate the effectiveness and safety of REVLIMID as maintenance therapy after auto-HSCT, but there were many differences in how the studies were conducted. Some differences between the studies include:

• Study location: Study 1 took place in the US; Study 2 took place in France, Belgium, and Switzerland
• Different therapy regimens before transplant (also called induction therapy). Study 1 included the use of REVLIMID-based induction therapy in some patients; Study 2 did not
• Use of a short course of additional therapy after transplant (also called consolidation therapy). Study 1 did not use consolidation therapy; Study 2 used consolidation therapy

These are not all of the differences between the studies. Talk to your doctor to understand what the study results may mean for you.
REVLIMID is only available through a restricted distribution program, REVLIMID REMS®.

Please see full Prescribing Information, including Boxed WARNINGS and Medication Guide, in pocket and Important Safety Information on pages 2-10.